Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NKX2-2
REST API REST API
Homo sapiens
NKX2-2 is differentially expressed in 140 experiments: 144 organism parts: amygdala, hypothalamus, ... (142 more);, 84 disease states: normal, Burkitt's lymphoma, ... (82 more);, 27 cell types 190 cell lines 17 compound treatments and 58 other conditions.
Synonyms NKX2B, NKX2.2
Orthologs Nkx2-2 (Mus musculus)   nkx2.2a (Danio rerio)   Nkx2-2 (Rattus norvegicus)   E1BBE1_BOVIN (Bos taurus)   nkx2-2 (Xenopus laevis)   NKX2-2 (Canis familiaris)   vnd (Drosophila melanogaster)   (Compare orthologs)
Gene Ontology Term protein binding, regulation of transcription, DNA-dependent, transcription, DNA-dependent, smoothened signaling pathway, transcription factor binding, cell differentiation, sequence-specific DNA binding, positive regulation of transcription from RNA polymerase II promoter, multicellular organismal development, transcription coactivator activity, nucleus, regulation of cell differentiation, nervous system development, chromatin binding, nucleoplasm, brain development, digestive tract development, intracellular part, positive regulation of neuron differentiation, spinal cord oligodendrocyte cell fate specification, pancreatic PP cell fate commitment, astrocyte differentiation, spinal cord motor neuron differentiation, ventral spinal cord interneuron fate determination, positive regulation of oligodendrocyte differentiation, negative regulation of neuron differentiation, positive regulation of cell differentiation, spinal cord oligodendrocyte cell differentiation, endocrine pancreas development, oligodendrocyte development, pancreatic A cell fate commitment, neuron fate specification, cell development, sequence-specific DNA binding transcription factor activity, core promoter proximal region DNA binding, type B pancreatic cell development, type B pancreatic cell fate commitment, positive regulation of sequence-specific DNA binding transcription factor activity
InterPro Term Homeobox, Homeobox_eu
UniProt Accession O95096
Search EB-eye ENSG00000125820
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-MTAB-24, E-MTAB-25, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-1880, E-GEOD-19639, E-GEOD-19397, E-GEOD-24147, E-GEOD-4717, ... (21 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
MDAMB453
2
E-MTAB-37, E-MTAB-62
C33A
1
E-MTAB-37
HuPT4
1
E-MTAB-37
NCIH358
1
E-MTAB-37
Y79
1
E-MTAB-37
184 more value(s).


Cell type

studied in E-MTAB-24, E-MTAB-25, E-GEOD-3920, E-GEOD-5099, E-TABM-145, ... (16 experiments)

Factor Value U/D Experiments
n/a
1
E-MTAB-24
B cell
2
1
E-GEOD-13987
plasma cell
1
E-MEXP-2360
platelet
1
E-GEOD-2006
leydig cell
1
E-MTAB-25
fibroblast
1
E-GEOD-3920
21 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-GEOD-2466, E-MTAB-62, ... (30 experiments)

Factor Value U/D Experiments
Burkitt's lymphoma
2
2
E-MTAB-37, E-GEOD-1880
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
neuroblastoma
2
E-GEOD-1825, E-MTAB-62
carcinoma in situ, bladder tumor
1
E-MTAB-62
chronic myeloid leukemia
1
E-MTAB-62
adrenocortical adenoma
1
E-TABM-311
78 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-MEXP-2218, E-GEOD-412, E-GEOD-2292, ... (11 experiments)

Factor Value U/D Experiments
none
3
E-GEOD-412, E-GEOD-2292, E-TABM-868
lipopolysaccharide
1
E-TABM-868
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
placebo
1
E-MEXP-1335
CNOT7+CNOT8
1
E-MEXP-2218
Cxcl12
1
E-GEOD-7307
11 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
43
1
1
E-GEOD-3494


Biopsy tissue
studied in E-GEOD-5851

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-19743, E-GEOD-1725

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-18995

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-MEXP-2359

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-1561, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Genotype
studied in E-GEOD-2466, E-MEXP-421, E-GEOD-2292

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1446, E-GEOD-22278, E-GEOD-837

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-GEOD-1926, E-GEOD-19519, E-GEOD-6919, E-MEXP-935, ... (18 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108

Injury
studied in E-GEOD-19743

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-TABM-84

Phenotype
studied in E-GEOD-21750, E-GEOD-3407, E-GEOD-17636

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254

Replicate
studied in E-GEOD-10797

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-1676, E-MEXP-1857, E-GEOD-3485, E-MEXP-2759

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-2466, E-GEOD-7540, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Tumor size
studied in E-GEOD-3494, E-GEOD-6532

Processing time: 0.505 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM